The 2008 study by Tilburgs and colleagues provided functional evidence that CD4+CD25bright regulatory T cells (Treg) accumulate in the human decidua and suppress fetus-specific maternal immune responses, and suggested that fetus-specific Treg are selectively recruited from maternal peripheral blood to the fetal-maternal interface. Eighteen years of subsequent work has refined the phenotypes of decidual Treg and identified local induction pathways, but two core questions remain open: the molecular mechanisms (and their relative contributions) by which decidual Treg, including fetus-specific ones, suppress maternal anti-fetal T-cell responses in humans, and the provenance of decidual fetus-specific Treg — peripheral recruitment versus local induction and expansion — for which no direct in-human evidence exists. Tilburgs's 2026 review still lists closely related questions as outstanding — what molecular mechanisms EVT utilize to increase and activate decidual Treg, and whether the maternal Treg response is specific for fetal HLA-C and/or other fetal minor histocompatibility antigens — and no study to date has demonstrated the provenance of decidual fetus-specific Treg or quantified the relative contributions of their suppressive pathways in humans.

Background

During pregnancy, the maternal immune system must tolerate fetal alloantigens — paternally inherited molecules foreign to the mother — while preserving anti-microbial defense. A key site of this tolerance is the decidua, the specialized mucosal lining of the pregnant uterus, where fetal placental cells known as extravillous trophoblasts (EVT) invade maternal tissue and directly contact maternal immune cells. In humans, EVT uniquely express the non-classical HLA-G molecule and are the only placental cells expressing the polymorphic HLA-C molecule, making fetal HLA-C a major target of maternal T-cell recognition.

Regulatory T cells (Treg) are a CD4+ T-cell lineage specialized for immune suppression, classically identified by high CD25 (the interleukin-2 receptor alpha chain) expression and the transcription factor FOXP3. Proposed suppressive mechanisms include CTLA-4 (a receptor that outcompetes the co-stimulatory receptor CD28 for the CD80/CD86 ligands on antigen-presenting cells), secretion of inhibitory cytokines such as IL-10 and TGF-β, consumption of IL-2, and generation of immunosuppressive adenosine via the ectoenzymes CD39 and CD73 — but their relative contributions in any human tissue are hard to establish because the mechanisms are redundant.

Tilburgs et al. (J Immunol 2008) showed that depleting CD4+CD25bright cells from maternal peripheral blood abolished suppressive activity against cord-blood cells of the mother's own child (but not third-party cord blood), while decidual CD4+CD25bright cells with a regulatory phenotype (FOXP3+, HLA-DR+) suppressed both fetus-specific and fetus-nonspecific responses. The authors concluded that the data "suggest a preferential recruitment of fetus-specific regulatory T cells from maternal peripheral blood to the fetal-maternal interface" — an inference from phenotypic and functional comparisons, not a direct demonstration of cell migration. The reported findings did not identify the inhibitory pathways used by decidual Treg and provided no direct evidence distinguishing recruitment from local expansion; these gaps, together with the assay and marker limitations of studying these cells, have been framed as open by the subsequent literature.

Later work has built on but not closed this question. Salvany-Celades et al. (Cell Rep 2019) identified three functional decidual Treg types in healthy pregnancy — CD25-high FOXP3+, PD1-high IL-10+ (PD1 being the co-inhibitory receptor programmed cell death protein 1), and TIGIT+ FOXP3-dim (TIGIT being another co-inhibitory receptor) — and showed in vitro that HLA-G+ EVT or decidual macrophages directly increase CD25-high FOXP3+ Treg from blood CD4+ T cells, and that EVT-induced PD1-high Treg suppress via IL-10, with their induction partially blocked by anti-HLA-C and anti-CD3 antibodies, suggesting antigen-dependent local induction. In mice, decidual chemokines (CCL2, CCL12, CCL20) recruiting CCR2/CCR6-bearing thymus-derived Treg, and local induction of peripheral Treg, both contribute. Sequencing of T-cell receptor (TCR) genes — whose rearranged DNA sequences act as heritable barcodes identifying each T-cell clone (a 'clonotype') — has made clonal tracking of cells between blood and tissue technically feasible, but it has not yet been applied to blood-versus-decidua Treg tracking in healthy pregnancy. Reviews through 2020-2026 consistently state that the origin and antigenic specificity of maternal decidual Treg remain poorly understood, that no reliable markers distinguish thymus-derived from peripherally induced human Treg, and that therapeutic manipulation of Treg in pathological pregnancy "remains in its infancy."

Problem Statement

Determine, in humans, the mechanistic basis of fetus-specific regulatory T-cell control at the maternal-fetal interface. This comprises two jointly linked questions: (i) By what molecular mechanisms — e.g. CTLA-4-dependent co-stimulation blockade, IL-10 or TGF-β secretion, IL-2 consumption, adenosine generation via CD39/CD73 — do decidual CD4+FOXP3+ Treg, including fetus-specific ones, suppress maternal T-cell responses against fetal alloantigens, and what are the relative contributions of these pathways in situ? (ii) What is the provenance of decidual fetus-specific Treg: are they selectively recruited from maternal peripheral blood (by which chemokine/trafficking axes), locally induced from naive CD4+ T cells upon recognition of fetal antigens presented by extravillous trophoblasts (EVT) or decidual antigen-presenting cells, locally expanded, or a combination — and can this be demonstrated directly (e.g. blood-decidua T-cell receptor (TCR) clonotype sharing, proliferation kinetics, or trafficking evidence) rather than inferred from phenotype? The suppressive-mechanism and provenance components are inseparable parts of a single account of how local tolerance to fetal alloantigens is established and maintained in healthy human pregnancy. Each part must be answered, not only framed, at a fixed level of form and precision: for (i), present the relative contributions of the candidate pathways as an explicit ranking — qualitative, or quantitative where human evidence permits — that names which pathway(s) predominate in decidual tissue, cites the human evidence constraining that ranking, and states which contributions current human data cannot resolve, taking the target population to be decidual CD4+FOXP3+ Treg as a whole, including but not restricted to the fetus-specific subset; for (ii), taking the target population to be the fetus-specific subset, (a) classify the provenance as selective peripheral recruitment, local induction, local expansion, or a combination, naming the chemokine/trafficking axis or inducing interaction invoked and the evidence type each rests on, and (b) state which evidence design(s) could demonstrate that provenance directly in humans rather than infer it from phenotype, assessing for each such design which of the provenance classes in (a) it can and cannot distinguish, so that a design whose discriminating power is insufficient is identified as such and the additional evidence needed to separate the classes it cannot resolve is specified. No new human experimentation is required for either part: (i) is resolved by ranking and weighing existing human evidence, and a negative answer to (ii)(b) is a legitimate completion, so a partial-pathway or proposed-method answer satisfies the task only when it states this form explicitly. Defects in the recruitment, localization or suppressive function of decidual Treg are associated with pregnancy complications such as recurrent miscarriage, preeclampsia and preterm birth, but whether such deficits are causal remains undemonstrated; this association provides the clinical motivation for resolving (i) and (ii).

References

  1. Tilburgs T, Roelen DL, van der Mast BJ, de Groot-Swings GM, Kleijburg C, Scherjon SA, Claas FH. Evidence for a Selective Migration of Fetus-Specific CD4+CD25bright Regulatory T Cells from the Peripheral Blood to the Decidua in Human Pregnancy. The Journal of Immunology 2008;180(8):5737-5745. DOI: 10.4049/jimmunol.180.8.5737. https://doi.org/10.4049/jimmunol.180.8.5737
  2. Salvany-Celades M, van der Zwan A, Benner M, Setrajcic-Dragos V, Bougleux Gomes HA, Iyer V, Norwitz ER, Strominger JL, Tilburgs T. Three Types of Functional Regulatory T Cells Control T Cell Responses at the Human Maternal-Fetal Interface. Cell Reports 2019;27(9):2537-2547. DOI: 10.1016/j.celrep.2019.04.109. https://doi.org/10.1016/j.celrep.2019.04.109
  3. Ahn SH, Nguyen SL, Petroff MG. Exploring the Origin and Antigenic Specificity of Maternal Regulatory T Cells in Pregnancy. Frontiers in Immunology 2020;11:1302. DOI: 10.3389/fimmu.2020.01302. https://doi.org/10.3389/fimmu.2020.01302
  4. Li Z, Liang X, Chen X, Chen Y, Wang F, Wang S, Liao Y, Li L. The role of thymus- and extrathymus-derived regulatory T cells in maternal-fetal tolerance. Frontiers in Immunology 2023;14:1109352. DOI: 10.3389/fimmu.2023.1109352. https://doi.org/10.3389/fimmu.2023.1109352
  5. Morgan JC, Hynes GE, Pollard JM, Andrade MS, Jeong JC, Chong AS. Hyporesponsive fetus-specific T cell responses in multiparous human pregnancy. Frontiers in Immunology 2025;16:1634430. DOI: 10.3389/fimmu.2025.1634430. https://doi.org/10.3389/fimmu.2025.1634430
  6. Koenig ZT, Eswar S, Tsuda S, Schuldt N, Chougnet CA, Forde B, Andorf S, Tilburgs T. Decidual CD4 Effector Memory and Resident Memory T Cells Respond to Cord Blood Allo-Antigens. American Journal of Reproductive Immunology 2026;95(2). DOI: 10.1111/aji.70213. https://doi.org/10.1111/aji.70213
  7. Tilburgs T. Decidual immune activation by extravillous trophoblasts drives maternal-fetal tolerance and immunity. Trends in Immunology 2026;47(3):180-183. DOI: 10.1016/j.it.2026.01.011. https://doi.org/10.1016/j.it.2026.01.011
  8. Saito S. Reconsideration of the Role of Regulatory T Cells during Pregnancy: Differential Characteristics of Regulatory T Cells between the Maternal-Fetal Interface and Peripheral Sites and between Early and Late Pregnancy. Medical Principles and Practice 2022;31(5):403-414. DOI: 10.1159/000527336. https://doi.org/10.1159/000527336
  9. Liu H, Huang W, Hu Z, Han J, Gao R, Qin L. Regulatory T cells in human pregnancy: mechanisms, dysregulation, and therapeutic perspectives. Frontiers in Immunology 2026;17:1815957. DOI: 10.3389/fimmu.2026.1815957. https://doi.org/10.3389/fimmu.2026.1815957
  10. Miller D, Romero R, Myers L, Xu Y, Arenas-Hernandez M, Galaz J, Soto C, Done B, Quiroz A, Awonuga AO, Bryant DR, Tarca AL, Gomez-Lopez N. Immunosequencing and Profiling of T Cells at the Maternal-Fetal Interface of Women with Preterm Labor and Chronic Chorioamnionitis. The Journal of Immunology 2023;211(7):1082-1098. DOI: 10.4049/jimmunol.2300201. https://doi.org/10.4049/jimmunol.2300201
  11. Li QH, Zhao QY, Yang WJ, Jiang AF, Ren CE, Meng YH. Beyond Immune Balance: The Pivotal Role of Decidual Regulatory T Cells in Unexplained Recurrent Spontaneous Abortion. Journal of Inflammation Research 2024;17:2697-2710. DOI: 10.2147/jir.s459263. https://doi.org/10.2147/jir.s459263